Identification and Characterization of a Liver Stage-Specific Promoter Region of the Malaria Parasite Plasmodium by Helm, Susanne et al.
Identification and Characterization of a Liver Stage-
Specific Promoter Region of the Malaria Parasite
Plasmodium
Susanne Helm
1, Christine Lehmann
1, Andreas Nagel
1, Rebecca R. Stanway
1¤, Sebastian Horstmann
1,
Manuel Llinas
2, Volker T. Heussler
1*
¤
1Malaria Laboratory 1, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, 2Carl Icahn Laboratory, Princeton University, Princeton, New Jersey, United
States of America
Abstract
During the blood meal of a Plasmodium-infected mosquito, 10 to 100 parasites are inoculated into the skin and a proportion
of these migrate via the bloodstream to the liver where they infect hepatocytes. The Plasmodium liver stage, despite its
clinical silence, represents a highly promising target for antimalarial drug and vaccine approaches. Successfully invaded
parasites undergo a massive proliferation in hepatocytes, producing thousands of merozoites that are transported into a
blood vessel to infect red blood cells. To successfully develop from the liver stage into infective merozoites, a tight
regulation of gene expression is needed. Although this is a very interesting aspect in the biology of Plasmodium, little is
known about gene regulation in Plasmodium parasites in general and in the liver stage in particular. We have functionally
analyzed a novel promoter region of the rodent parasite Plasmodium berghei that is exclusively active during the liver stage
of the parasite. To prove stage-specific activity of the promoter, GFP and luciferase reporter assays have been successfully
established, allowing both qualitative and accurate quantitative analysis. To further characterize the promoter region, the
transcription start site was mapped by rapid amplification of cDNA ends (59-RACE). Using promoter truncation experiments
and site-directed mutagenesis within potential transcription factor binding sites, we suggest that the minimal promoter
contains more than one binding site for the recently identified parasite-specific ApiAP2 transcription factors. The
identification of a liver stage-specific promoter in P. berghei confirms that the parasite is able to tightly regulate gene
expression during its life cycle. The identified promoter region might now be used to study the biology of the Plasmodium
liver stage, which has thus far proven problematic on a molecular level. Stage-specific expression of dominant-negative
mutant proteins and overexpression of proteins normally active in other life cycle stages will help to understand the
function of the proteins investigated.
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Introduction
Malaria remains one of the main health burdens in developing
countries, especially in sub-Saharan Africa. Much recent work on
developing vaccines against the Plasmodium parasite, the causative
agent of the disease, has concentrated on the liver stage of the
parasite [1]. The liver stage is particularly attractive for vaccine
development as it presents a chokepoint in parasite development
where low numbers of parasites are present [2]. However, there is
a great discrepancy between the Plasmodium liver stage being the
main target of vaccine development against malaria and our
knowledge of the biology of the parasite at this particular stage. To
facilitate studies on the liver stage of development, we sought to
generate a highly specific liver stage reporter.
Transcriptomic and proteomic analyses of the parasite at
various life cycle stages suggest stage-specific regulation of gene
expression but nothing is known about the regulation of
transcription during the liver stage. Recently, the ApiAP2
transcription factor family has been suggested to regulate stage-
specific gene expression in the human parasite Plasmodium
falciparum [3,4]. However, these in vitro investigations thus far have
only been conducted on the blood stage of the parasite. Recently,
ApiAP2 regulators for sporozoite and ookinete development in P.
berghei have been characterized, showing for the first time that
there are stage-specific transcription factors governing parasite
development [5,6]. However, no liver stage-specific promoters
have thus far been described. There may indeed be a relatively
small number of tight promoters specific for this stage, due to the
similarities between the liver stage and other stages and
particularly as the ultimate end of both liver and asexual blood
stage development is the production of merozoites. The aim of this
study was to identify in the rodent model parasite P. berghei a liver
stage-specific promoter and to verify its stage-specific expression
using GFP and luciferase reporter assays.
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In search of a truly liver stage-specific promoter, we analyzed
mRNA expression of a number of genes predicted to be liver
stage-specifically expressed in Plasmodium yoelii [7] and concentrat-
ed on PY05129. This gene has been identified in a recent DNA
microarray study as expressed solely during the liver stage [8]. We
chose to analyze the P. berghei ortholog of PY05129,
PB103464.00.0 (PBANKA_100300 in GeneDB), which we find
to also be exclusively expressed during the mid to late P. berghei
liver stage (Figure 1). PB103464.00.0 and PY05129 have a close
homology on an amino acid level and their upstream putative
promoter regions also show a close similarity. The most recent
release of PlasmoDB (version 7.0, September 2010) shows
PBANKA_100300 to have syntenic homologs in all sequenced
Plasmodium genomes, with the P. falciparum homolog being
PFD0260c. Between the start codon of the PB103464.00.0 gene
and the next gene upstream, a region of 989bp is present.
(Supplementary Figure S1). We concluded that the minimal
promoter of PB103464.00.0 is located within this region and
cloned the 2989/+1 gDNA fragment into a P. berghei transfection
plasmid upstream of gfp (Figure 2A, upper panel) to confirm its
stage-specific activity. The generated plasmid pGFP103464 was
transfected into P. berghei and a parasite strain, PbGFP103464, was
established. A parasite line in which GFP is constitutively
expressed under the control of the pbeef1aa promoter (abbreviated
in plasmid and parasite names as ef1a) was chosen as a control for
promoter activity (Figure 2A, lower panel). Live imaging of blood
stages, oocysts and of in vitro liver stages was performed. GFP
expression driven by the PB103464.00.0 59 upstream region was
restricted to the liver stage (Figure 2B, upper panel), confirming
that the chosen 59 upstream region indeed contains a liver stage-
specific promoter. As expected, GFP expression under the control
of the constitutive pbeef1aa promoter was detectable in all stages
analyzed (Figure 2B, lower panel). During parasite development
in hepatocytes, GFP expression under the PB103464.00.0
promoter was strongly upregulated at 48 hpi and continued until
merosome formation, the end-point of liver stage development.
Although the GFP expression findings supported our mRNA
transcription studies, the analysis of GFP expression has its
limitations as it does not allow an accurate quantitative analysis of
promoter activity. We therefore decided to clone the promoter
region in front of the firefly luciferase (FL) gene [9] and to
normalize the measurement of firefly luciferase activity by
including in the same plasmid a Renilla luciferase (RL) gene [10]
under the control of a constitutive promoter (Figure 3A). This
plasmid was named pFL103464RLef1a. As a control, a further
plasmid was constructed in which both luciferase genes were under
the control of the constitutive promoter (pFLef1aRLef1a)
(Figure 3A). Both plasmids were transfected separately into P.
berghei and the parasite strains PbFL103464RLef1a and PbFLef1aR-
Lef1a, were established. The plasmids used allow integration into
the P. berghei d/c ssu rRNA locus, but are also able to persist in the
parasite population as episomes. As both luciferases are encoded
on each plasmid and therefore the genes are always present in
equal numbers, it was not necessary to analyze genetically whether
the parasite populations contained integrated or episomal gene
copies or (as is most likely) a mixture of both. Transfection of a
single plasmid carrying both luciferase genes has great advantages
over traditional co-transfection of two plasmids each containing a
single luciferase gene, which results in a mixture of single- and
double-transfectants, meaning that cloning must be performed to
produce a population where each plasmid is integrated only once.
In P. berghei, such limiting dilution cloning requires the use of
numerous mice. As transfection with the single plasmids described
above results in parasites that contain equal copy numbers of each
gene, this strategy greatly simplifies later analysis and also
potentially saves large numbers of mice.
Using the above parasite strains, we determined the relative
expression level of FL compared to RL in the blood stage, in
oocyst and salivary gland sporozoites and in the liver stage (in
infected hepatoma cells) at 48 hpi using a dual-luciferase assay
(Figure 3B). FL expression of the parasites PbFL103464RLef1a was
absent during the blood and mosquito stage and was seen to only
be high during the liver stage, confirming the GFP expression
results and also the transcription profile of the PB103464.00.0
gene determined by RT-PCR (Figures 1, 2). Most importantly,
the luciferase assays clearly show that the PB103464.00.0
promoter region is very tightly silenced during blood and insect
stages. During the liver stage in vitro, the PB103464.00.0 promoter
region is significantly more active at 48 hpi than the constitutive
pbeef1aa promoter (P#0.001 by two-tailed unpaired t-test). The
PbFLef1aRLef1a parasites, in which both luciferase genes are
independently expressed under the pbeef1aa promoter showed
constitutive expression of both luciferase genes. Unexpectedly,
however, the ratios of FL/RL expression varied at different life
cycle stages. The reason for this variation is not clear but since
both luciferase genes are transcribed under the control of the
same constitutive promoter, it is likely that differing protein
stability of the two luciferases at different life cycle stages is
responsible.
As an additional control, we decided to compare the liver stage-
specific promoter to a promoter that is mainly active in
another parasite stage. To this end, we first performed database
searches and RT-PCR assays and identified PB000869.01.0
(PBANKA_040200, abbreviated in plasmid and parasite names
as 869), as being expressed at a low level in the liver relative to
other stages (data not shown). We cloned the 59 upstream region of
this gene in front of the FL resulting in the plasmid pFL869RLef1a
(Figure 4A). Transfection of this plasmid into P. berghei resulted in
the generation of the parasite strain PbFL869RLef1a. The
PbFL869RLef1a parasites showed a high firefly luciferase
expression in sporozoites but nearly no FL activity in the blood
and oocyst stage as well as in vitro in early liver stages (Figure 4B).
FL/RL expression in these parasites was compared to
that of PbFL103464RLef1a parasites (Figure 4C). Whereas
PbFL103464RLef1a parasites exhibited an increasing FL activity in
the liver stage from 24 hpi onwards, FL activity for PbFL869RLef1a
parasites was only found at 48 hpi and later stages, which roughly
correlates with the onset of merozoite formation. At very late stages
(detached cells/merosomes), FL activity of the PbFL103464RLef1a
Figure 1. Liver stage-specific gene expression. (A) Results of RT-
PCR analysis of PB103464.00.0 mRNA expression, comparing blood
stage (BS), oocysts (Oo) and in vitro liver stage (LS) 48 hpi. Total RNA
was extracted, and RT-PCR reactions were performed with (+)o r
without (2) reverse transcriptase (negative control). RT-PCR analysis of
tubulin mRNA expression served as a control.
doi:10.1371/journal.pone.0013653.g001
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development of blood cell-infective merozoites.
Having confirmed a strict liver stage-specific activity of the
promoter region of the gene PB103464.00.0 (2989/+1) we sought
to determine possible transcription factor binding sites in this
region. Since Plasmodium mRNAs often contain long 59 untrans-
lated regions (UTRs), which are unlikely to provide potential
binding sites for transcription factors we first identified the
transcription start site (TSS) for PB103464.00.0. Using 59 RACE
technology to amplify the 59 untranslated region (Figure 5A) the
RACE products were sequenced, revealing a TSS at position
2318 (Figure 5B, C) restricting the DNA region interacting with
transcription factors to between position 2989 to 2318. By
bioinformatic analysis, we searched this region for sequence motifs
known in P. falciparum to allow binding of different ApiAP2
transcription factors [4] and identified four potential binding sites
for PB000252.02.0 (PBANKA_090960 in GeneDB, homolog of
PF11_0404), although additional non-ApiAP2 binding sites might
also exist (Supplementary Figure S2). To analyze the effect
of the individual binding sites it is important to determine the basal
transcription in the absence of these sites. To this end the 2318/
+1 region was cloned in front of the FL gene in the dual luciferase
plasmid (pFL103464(-318)RLef1a). Transfection of this plasmid into
P. berghei resulted in the generation of the parasite strain
PbFL103464(-318)RLef1a. This parasite strain did not show a
significant FL activity in liver stage parasites (Figure 6)o r
any other parasite stage investigated, confirming that the actual
promoter region must be localized between position 2989
and 2318. We next generated the parasite strain
PbFL103464(2775)RLef1a to analyze whether the promoter region is
positioned between 2775 and +1. In this region two of the four
predicted PB000252.02.0 ApiAP2 binding sites were found. Two
additional sites were found between the excluded region 2989
and 2775 (Supplementary Figure S2). We detected a
significant but not complete reduction in FL activity in
the PbFL103464(2775)RLef1a parasites compared to the
PbFL103464RLef1a parasites, suggesting that both the excluded
sequence 2989/2775 and the 2775/+1 region contain functional
portions of the promoter. Deletion experiments do not allow the
exact identification of transcription factor binding sites and
therefore we mutated one predicted ApiAP2 binding site (at
position 2825/2818), with the sequence TAGAACA [4]. To our
surprise, the mutation resulted in an increased luciferase activity,
suggesting that the transcription factor binding to this particular
ApiAP2 site acts as a repressor (Figure 6). Interestingly, the
mutationdidnotresultinincreasedluciferase levelsinotherparasite
stages and so the liver stage-specific transcription profile was
maintained.
Our data have identified a promoter region derived from
PB103464.00.0 that is able to direct exclusively liver-stage
expression of genes of interest. In future experiments we will
investigate the role of the predicted transcription factor binding
Figure 2. Promoter-dependent GFP expression. (A) The vector pGFP103464 with GFP under the control of the promoter region 103464 and the
vector pGFPef1a with GFP under control of the ef1a promoter were generated and their transfection resulted in the parasite lines PbGFP103464 and
PbGFPef1a. (B) Live imaging of PbGFPef1a and PbGFP103464 parasites at different life cycle stages. HepG2 cells were infected with transgenic P. berghei
sporozoites and analyzed at different time points after infection (hpi, hours post-infection). GFP expresion was monitored by fluorescent microscopy.
DNA was stained with Hoechst 33342. Arrows indicate young liver stage parasites. (iRBC: infected red blood cell; LS: liver stage) Scale bars: 10 mm.
doi:10.1371/journal.pone.0013653.g002
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bioinformatic and experimental approaches.
Discussion
Several liver stage-specifically expressed genes have been
described in the literature [11,12,13,14] but previous studies have
not analyzed the promoters of these genes. We describe here for
the first time a promoter region that is only active during the liver
stage. In vitro it is only possible to achieve relatively low rates of
hepatoma cell infection by Plasmodium sporozoites, which makes
biochemical analysis of the liver stage very difficult. Luciferase
reporter assays have proved to be extremely useful for the
detection of minute numbers of parasites in the blood of infected
mice [15] and therefore we decided to employ a dual-luciferase
assay to quantitatively analyze promoter activity in vitro. Using this
very sensitive technique, it is possible to analyze promoter activity
of any given gene in all life cycle stages.
The results of this study verified that the 2989/2318 promoter
region of PB103464.00.0 is sufficient for gene expression to be
restricted to the liver stage. This is perhaps surprising since
Plasmodium parasites have been seen to use other cis-regulatory
elements around the TSS, in introns and in the 39 region of genes
to control mRNA expression [16,17,18,19]. Epigenetic alterations,
which might differ substantially in the transfected versus the
endogenous promoter region, due to their differing positions
within the genome, seem not to play an important role in the case
of the PB103464.00.0 promoter region.
We further showed that the deletion of the 2989/2775 region
caused a significant reduction in but not complete abolishment of
luciferase expression, suggesting that the minimal promoter
includes distantly situated motifs. Interestingly, the deletion did
not result in an altered expression profile in other parasite stages
indicating that the remaining 2775/+1 region is sufficient to
guarantee liver stage-specific expression, albeit at a reduced level.
Bioinformatic analysis of the entire 2989/2318 region
revealed the existence of four putative binding sites that could
be recognized by the ApiAP2 protein PB000252.02.0, based on
homology with the P. falciparum protein PF11_0404. Two were
found in the 2989/2775 region and the two others in the 2775/
2318 region. It has been suggested that ApiAP2 transcription
factors are involved in stage-specific gene regulation since several
Figure 3. Generation of plasmids and transgenic P. berghei parasites for use in dual-luciferase assays. (A) The vector pFL103464RLef1a with
FL under the control of the promoter region 103464 and RL under the control of the ef1a promoter was generated and its transfection resulted in the
parasite line PbFL103464RLef1a. The plasmid pFLef1aRLef1a with FL and RL under the control of the ef1a promoter was used to obtain control parasites
PbFLef1aRLef1a. Diamonds represent 39UTRs, which in all cases were from the pbdhfr/ts gene. In the upper plasmid, the selection marker (tgdhfr/ts)i s
displayed but for simplicity in all other plasmid diagrams only those genes and features directly related to the experiments described are displayed.
(B) Comparison of the luciferase activity (FL expression relative to RL expression) of transgenic parasites during the blood stage (BS), in oocysts (Oo),
in salivary gland sporozoites (Sp) and in vitro in the liver stage (LS), 48 hours post-infection (hpi) of hepatoma cells. Standard deviation values (shown
as error bars) were determined from three different measurements. Statistical analysis was performed using two-tailed unpaired t-tests (*P,0.05;
***P,0.001).
doi:10.1371/journal.pone.0013653.g003
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during the blood stage [4]. It is tempting to speculate therefore,
that these ApiAP2 proteins would play important roles during
either the mosquito or liver stages. Two reports have already
documented that the elimination of a single ApiAP2 gene is
sufficient to prevent the development of either ookinetes or
sporozoites [5,6]. Interestingly, homologs of these genes in P.
falciparum are expressed additionally in the asexual stages, implying
that they have roles across diverse stages. Of course, it is possible
that other transcription factors might also be involved in regulating
expression via the 2989/+1 region, including the canonical
TATA-box-binding protein that has been identified in the P.
falciparum genome [19,20]. The finding that a mutation of one
predicted ApiAP2 binding site in our promoter of interest lead to
an increase in luciferase activity suggests that ApiAP2 proteins
could have not only an activator but also a repressor function in
the control of PB103464.00.0 expression.
A systematic dissection of the PB103464.00.0 promoter region is
a major undertaking since it includes the generation of numerous
parasite strains, which must all be generated by transfection of
blood stage schizonts, requiring many mice. Additionally, the
parasites need passage through mosquitoes before they can finally
be used to infect hepatic cell lines. Sequential deletion of promoter
regions will provide useful information about the possible
transcription factor binding sites. However, since our results
suggest that several regions are likely involved in regulating
expression and because deletions affecting the distance of putative
elements could disturb the functionality of putative control
elements, other techniques such as linker scanning approaches
may also have to be applied [21]. Bioinformatic approaches to
search for motifs common to exclusively liver stage promoters will
allow for focused mutation-based strategies, limiting the number of
parasite strains to be generated and hence the usage of mice. A
prerequisite for this approach is the identification of other liver
stage-specific promoters and their comparison with the
PB103464.00.0 promoter region. In a first attempt, we compared
this promoter with the 59 upstream region of the liver stage specific
protein LISP1 [22] and found that the LISP1 promoter, like that
of PB103464.00.0, contained putative binding sites for the ApiAP2
protein PB000252.02.0 (the homolog of PF11_0404). However, no
Figure 4. Comparison of the activities of promoter regions of the genes PB000869.01.0 and PB103464.00.0 during different life
cycle stages. (A) Plasmid map of pFL869RLef1a, used to generate the parasites PbFL869RLef1a, which express Renilla (RL) and firefly (FL) luciferases
under the control of the pbeef1aa and the PB000869.01.0 promoter region, respectively. The diamond represents the 39UTR of the pbdhfr/ts gene. (B)
PB000869.01.0 promoter activity in respect to the constitutive promoter pbeef1aa, which was set to 100%. PbFL869RLef1a and PbFLef1aRLef1a parasites
were harvested at different life cycle stages (BS; blood stage, Oo; oocysts, Sp; salivary gland sporozoites, LS 24 hpi; liver stage 24 hours post-infection
in vitro), the ratio of FL to RL expression was determined and the percentage of luciferase activity of PbFL869RLef1a parasites was calculated relative to
that of PbFLef1aRLef1a parasites. (C) Comparison of luciferase activity in the parasites PbFL103464RLef1a and PbFL869RLef1a during the liver stage, as
determined by the ratio of FL to RL expression. Standard deviation values (shown as error bars) were determined from three different measurements.
doi:10.1371/journal.pone.0013653.g004
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promoters and it might be necessary to employ other methods to
identify additional transcription factor binding sites.
Proteins expressed solely at the liver stage are themselves
interesting for study and might be useful candidates for subunit
vaccine approaches. These proteins are likely to reveal novel liver
stage-specific pathways or metabolic processes that could be
targeted to eliminate or attenuate the parasite during this stage.
For example, it has recently been demonstrated that fatty acid
metabolism is essential only for liver stage parasites but not for
other stages [23]. Given the current focus on the possibility of
vaccines targeted against liver stage parasite development, using
either radiation or genetically attenuated parasites, such studies
are likely to provide new leads for vaccine development.
To better understand the biology of the Plasmodium liver stage, it
is essential to analyze the functions of proteins expressed at this
stage. To this end reverse genetics stands out as an excellent tool,
although its utility is frequently complicated in Plasmodium.
Transfection must be performed during the blood stage and any
genes with an essential function here cannot be targeted by
traditional knockout approaches [24]. For study in the liver stage,
the protein of interest must also be dispensable during develop-
ment within the mosquito. Recently a very elegant system has
been developed that allows the control of the expression levels of a
protein of interest by its fusion with a destabilization domain. This
system has been used successfully in Plasmodium falciparum blood
stage parasites [25]. However, the system relies on the constant
application of the ligand Shld1, which binds to the fused
Figure 5. Identification of the transcription start site (TSS) of the promoter region of PB103464.00.0. (A) Schematic representation of
the promoter region. A flag at position 2318 shows the TSS. The primers used for the 59-RACE are indicated. (B) The RACE product, obtained from the
second PCR amplification, was analyzed by gel electrophoresis. (C) The 59 UTR of PB103464.00.0 with the start codon, shown in bold. The arrow
indicates the TSS of the promoter region.
doi:10.1371/journal.pone.0013653.g005
Figure 6. Promoter deletion affects expression of FL. Parasites transfected with the plasmid pFL103464RLef1a carrying the complete promoter
region (2989/+1), promoter deletions (PbFL103464(2775)RLef1a (2775/+1) and PbFL103464(2318)RLef1a (2318/+1)) or a promoter mutation
(PbFL103464(*825)RLef1amut-825/2818)were passed through mosquitoes and used for HepG2 cell infections. 48 hpi cells were harvested and dual-
luciferase assays of the cell extracts were performed. The FL/RL ratio obtained from extracts of parasites transfected with the plasmid pFL103464RLef1a
was set to 100% and the FL/RL ratio obtained from the parasite strains transfected the other constructs was calculated.
doi:10.1371/journal.pone.0013653.g006
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as this is unlikely to be possible during mosquito stages, the
method cannot yet be used for studying the consequences of
protein depletion during either the mosquito or liver stages.
Conditional or inducible knockouts are useful methods to study
essential genes [24,26] but these systems rely either on the stage-
specific expression of a recombinase or other regulatory proteins.
The liver stage-specific promoter described in this study might be
useful for the expression of such proteins. A liver stage-specific
promoter could also be used for the expression of dominant-
negative mutant proteins to study protein function specifically in
the liver stage or for the expression of proteins that cause adverse
effects on the parasite when expressed constitutively. In summary,
the identification and the use of a liver stage-specific promoter of
P. berghei will have a great impact in the analysis of the parasite
liver stage, an area fundamentally lacking in understanding.
Materials and Methods
Experimental animals and parasites
Mice used in experiments were of the NMRI strain, between 6
and 10 weeks of age and were bred in-house at the Bernhard
Nocht Institute for Tropical Medicine (Hamburg, Germany) or
supplied by Charles River Laboratories. All animal work was
conducted in compliance with regulations created and approved
by the ethical committee of Hamburg state authorities (Nr. FI
28/06).
RT-PCR
Total RNA was isolated from 0.05% saponin-treated (Sigma)
blood stage parasites, 20 infected mosquito midguts day 14 after
infection and infected HepG2 cells 48 hours after infection using
the NucleoSpinH RNA Extract Kit II (Macherey-Nagel). First
strand cDNA was synthesized using random primers (Invitrogen)
and Superscript
TMII reverse transcriptase (Invitrogen) according
to the manufacturer’s instructions. Target cDNAs were amplified
using GoTaqH DNA polymerase (Promega) and the following
primer sets: 59-AACAGCAATATATCGTCACCAAG-39 and 59-
GCACACGGAAATCATTTTGTT-39. As in internal control, P.
berghei tubulin cDNA was amplified using the primer 59-
TGGAGCAGGAAATAACTGGG-39 and 59- ACCTGACA-
TAGCGGCTGAAA-39.
Mapping of the transcription start site (59-RACE)
The transcription start site (TSS) of the promoter region 103464
was determined by 59 rapid amplification of cDNA ends (59-
RACE) based on the CapFinder method by Schramm et al., 2000
[27]. 1 mg RNA of P. berghei infected HepG2 cells isolated 48 hpi
(NucleoSpinH RNA II Kit, Macherey-Nagel) was reversed
transcribed by Superscript
TMII (Invitrogen) using a gene-specific
primer R197 59-ACATCCGTATTTTTCCTATTGACA-39 and
the CapFinderB [27]. cDNA was then amplified by PCR using
a gene-specific nested reverse oligonucleotide R130 59-
TGCTGTTGTATTTTTGTTTTTCATC-39 and the 59-Primer
[27]. The amplification products were cloned into the pGEMH-T
easy vector (Promega), DNA was extracted from 10 individual
transformants and sequenced.
Cell culture and in vitro infection of HepG2 cells
Human hepatoma cells (HepG2) were obtained from the
European cell culture collection and were maintained in complete
MEM (cMEM) with Earle’s Salts Medium supplemented with 10%
heat-inactivated FCS (foetal calf serum), 1% L-Glutamine, 1%
penicillin/streptomycin (all purchased from PAA Laboratories,
Austria). Cells were kept at 37uC in a 5% CO2 cell incubator and
split every 3–4 days by trypsinization.
1610
5 HepG2 cells were seeded into glass bottom dishes
(WillCo Wells BV, Netherlands) for live cell imaging or 5610
4
HepG2 cells into each well of a 24 well plate. Sporozoites were
prepared from dissected salivary glands of P. berghei-infected
Anopheles stephensi mosquitoes and incubated in media with HepG2
cells for 1–2 hours. After washing, the cells were incubated with
cMEM, as described above, containing Amphotericin B at
2.5 mg/ml (PAA Laboratories, Austria) at 37uC and 5% CO2
for indicated times.
Live cell imaging and live staining
Live imaging was performed with a Zeiss Axiovert 200 inverted
microscope and images taken and processed with the Improvision
software Openlab 5.0.1. Cell and parasite DNA staining was
carried out by incubation with 1 mg/ml Hoechst 33342 (Sigma) for
20 min at 37uC and 5% CO2.
For live imaging of P. berghei blood stages, tail blood was taken
from an infected mouse, mixed with room temperature cMEM
(see above) containing 1 mg/ml Hoechst 33342 (Sigma) and
microscopically analyzed. Midguts of infected A. stephensi mosqui-
toes were dissected for live imaging and microscopically
investigated.
Dual-luciferase assays
To determine the blood stage luciferase expression in the
transgenic P. berghei lines, 10 ml of tail blood of an infected mouse
was lysed for 15 min at 30uC with 100 ml 1x Passive Lysis Buffer
(PLB) obtained from the Dual-LuciferaseH Reporter (DLR
TM)
Assay System (Promega). For measuring luminescence in the
mosquito stage of the parasite, 5 midguts (day 14 after infection) or
salivary glands of three infected A. stephensi mosquitoes were
removed and lysed with 100 ml 1x PLB as above. For analyzing
the liver stages of the transgenic P. berghei lines, HepG2 cells were
infected with sporozoites (see above). At different time points after
infection the culture medium was removed and the cells washed
once with PBS, before lysis in 100 ml 1x PLB for 15 min at 30uC.
Samples were processed according to the protocol of the kit.
Briefly, after centrifuging the samples for 30 s at 12,000 g, 20 mlo f
the supernatant was added to 100 ml of Luciferase Assay Reagent
II. Luminescence was measured in a single tube Junior LB 9509
luminometer (Berthold Technologies). After a 10 second mea-
surement period 100 ml 1x Stop & GloH Reagent was added to the
tube to stop the firefly and activate the Renilla luminescence. The
output of the luciferase assays was in relative light units (RLU). All
assays were performed in triplicate. Either uninfected mosquitoes
or HepG2 cells were used as negative controls, as appropriate.
Samples can be collected and stored at 220uC to perform one
combined dual luciferase assay.
For calculation of the promoter activity, the mean RLU value of
control samples was subtracted from the mean RLU value of
experimental samples. The ratio of the firefly and the Renilla
luciferase RLUs indicated the activity of the promoter of interest.
Promoter activity curves were generated and statistical analysis of
the data performed using MS Office Excel and the GraphPad
Prism software (GraphPad Prism software Inc., US). Significance
levels were calculated with two-tailed unpaired t-tests.
Generation of transgenic P. berghei parasites
For analyzing the promoter region of PB103464.00.0,
the forward oligonucleotide 59-CGGATATCGTTGCAT-
TATCGTCAAAAGTG-39 and the reverse oligonucleotide 59-
CGGGATCCTTTTTATGTGTAAAAAAGTAAAATGATT-39
Plasmodium Promoter Region
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Taq High-Fidelity DNA polymerase (Finnzyme) from P. berghei
gDNA (underlined nucleotides represent EcoRVa n dBamHI
restrictions sites, respectively). The promoter region of
PB103464.00.0 was used to replace the pbeef1aa promoter in
EcoRV-BamHI-digested pL0017 vector (obtained through the MR4
(MRA-786), deposited by C. Janse) to create the plasmid pGFP103464.
For the dual-luciferase assay, plasmids with the firefly (FL) and
the Renilla (RL) luciferase were generated. The firefly luciferase
gene was amplified by PCR from pBI-GL (Clontech) and was used
to replace the GFP in the pL0017 vector to generate pFLef1a. The
same procedure was performed to generate the plasmid pRLef1a,
amplifying the Renilla luciferase (RL) gene by PCR from phRL-
CMV (Promega). The pbeef1aa promoter of the pFLef1a plasmid
was replaced with the promoter region of PB103464.00.0 to create
plasmid pFL103464. For the generation of the double-luciferase
plasmid, the entire cassette for RL expression under the control of
the pbeef1aa promoter (including the 39 UTR of Pbdhfr) was
amplified by PCR and ligated into pFL103464 and pFLef1a plasmids
to generate pFL103464RLef1a and pFLef1aRLef1a, respectively.
The plasmid pFL869RLef1a was generated similarly having first
amplified fragment 869, a 1 kb fragment upstream of PB000869.01.0,
by PCR using the primers 59-GGCCGCGGCCGCGTCTAAAG-
CATACAATAACTCTTAC-39 and 59-CTAGCCTAGGTTTG-
TATATTTCTGAGATTCCAAAAAAA-39.
For further analysis of the 103464 promoter region, the 59-
truncation fragments of the promoter were obtained by PCR
using the reverse primer 59-CGGGATCCTTTTTATGTG-
TAAAAAAGTAAAATGATT-39 and either the forward primer
59-GCGCGGCCGCAAAATAAAACGAATAACGATGTGA-39
(truncation -775/+1) or 59-GCGCGGCCGCATATAAAAAACA-
CACTAAAAATATATAATTAAAT-39 (truncation 2318/+1)
(underlined nucleotides represent NotI restriction site). Mutagenesis
PCR was performed to mutate the putative ApiAP2 binding site at
2825/2818 of the 103464 promoter from TAGAACAA to
TTATTATT. The truncated and mutated promoter
fragments were used the replace the original promoter region
of PB103464.00.0 in the plasmid pFL103464RLef1a and
transfection resulted in the parasites PbFL103464(2775)RLef1a,
PbFL103464(2318)RLef1a and PbFL103464(*825)RLef1a.
P. berghei schizont stages (ANKA strain) were transfected with
ApaI-SacII-linearized plasmid DNA (5–10 ng). Transgenic para-
sites were selected by pyrimethamine treatment [28].
Supporting Information
Figure S1 Detailed cloning strategy for testing activity of the
PB103464.00.0. promoter region. The entire region between gene
PB103463.00.0. and PB103464.00.0. was cloned in the plasmid
pL0017 in front of the gfp cDNA.
Found at: doi:10.1371/journal.pone.0013653.s001 (0.08 MB TIF)
Figure S2 DNA sequence of the PB103464.00.0. promoter
region. The transcription start site at position -318 and potential
ApiAP2 binding sites are labeled in colours. Since no data are
available on P. berghei ApiAP2 transcription factors, the P. falciparum
ApiAP2s, which would bind the indicated sequences are depicted.
Found at: doi:10.1371/journal.pone.0013653.s002 (1.30 MB TIF)
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